

A 65-year-old patient with non-small cell lung cancer (NSCLC) is being evaluated for targeted therapy. Molecular testing of the tumor biopsy revealed an EGFR exon 19 deletion, making the patient a suitable candidate for treatment with a tyrosine kinase inhibitor such as osimertinib.